Sponsor Dossier
Lundbeck
Sponsor Dossier for Lundbeck. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABILIFY
- Brand: BRINTELLIX
- Brand: CIPRAMIL
- Brand: CLOPIXOL
- Brand: EBIXA
- Brand: FLUANXOL
- Brand: LEXAPRO
- Brand: REXULTI
About
Lundbeck is an Australian Private Company with ABN 86070094290, based in New South Wales. The company is registered for GST and maintains an active entity status.
Portfolio
Lundbeck has nine brands on the ARTG, all of which are indexable. All nine brands have Product Information on file. Six brands are PBS-listed, six have PBAC outcomes on record, and two have AusPARs on record. Notable brands in the portfolio include Abilify, Brintellix, Cipramil, Clopixol, Ebixa, Fluanxol, Lexapro, Rexulti and Vyepti.
Therapeutic focus —
Neurology: 7 brands — Psychiatry: 1 brand — Oncology: 1 brand
PBS footprint
Six of Lundbeck's brands are PBS-listed, with the portfolio most recently touching the PBS schedule on 1 May 2026.
Regulatory activity
Lundbeck's most recent PBAC outcome was recorded on 1 July 2025, with six brands holding PBAC outcomes on record. The most recent AusPAR was issued on 9 June 2021, with two brands holding AusPARs on record.